# BEAT-meso (NCT03762018)

> BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03762018
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: ETOP IBCSG Partners Foundation
- Conditions: Pleural Mesothelioma Malignant Advanced
- Interventions: Carboplatin; Pemetrexed; Bevacizumab; Atezolizumab
- Enrollment: 400
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 37
- Podcasts: 8
- YouTube: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=beat-meso-nct03762018

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03762018", "email": "<work email>"}; the inbox owner confirms by the emailed link.